Emgality versus Nurtec ODT head-to-head migraine preventive treatment study now enrolling patients.

The study is evaluating once-monthly Emgality (galcanezumab-gnlm) injection compared to Nurtec ODT (rimegepant), a tablet patients take every other day, on patient-centric measures, including reductions in monthly migraine headache days and quality of life improvement.

While Nurtec ODT and Emgality are both medications that target CGRP, because Emgality is a monoclonal antibody (mAb) that binds to CGRP (a protein found in the brain thought to play a key role in migraine), it works differently than gepants like Nurtec ODT, that bind to and block the CGRP receptor. Emgality is the only CGRP medication with greater than 50%, greater than 75% and 100% reductions of monthly migraine headache days in its label for people with episodic migraine experiencing 4 to 14 migraine headache days per month. Lilly's CHALLENGE-MIG study aims to deepen the understanding of CGRP monoclonal antibodies (mAbs) compared to oral gepants in the preventive treatment of migraine and answer important questions that will help physicians and patients make informed treatment decisions.

"Migraine can greatly impact day-to-day activities, robbing people of their routines and their everyday and special occasions in life. Reducing the frequency of migraine attacks can help people achieve more migraine-free days and enjoy an improved quality of life; both of which are essential treatment goals," said Shivang Joshi, a trial investigator and neurologist at Dent Neurologic Institute. "Lilly's CHALLENGE-MIG study will help us understand how different types of preventive medications (CGRP mAbs vs. gepants) may help people achieve the goals that matter most to them. It's exciting that insights generated in this first-of-its-kind head-to-head trial will be able to spark treatment plan discussions between people with migraine and their health care providers."